Objectives: To investigate the occurrence and characteristics of ESBL/AmpC-producing Escherichia coli in faecal samples from horses at one equine clinic in the Netherlands.
Introduction
There is an increased concern about Enterobacteriaceae, particularly Escherichia coli that produce ESBLs or AmpC b-lactamases and confer resistance to third-and fourth-generation cephalosporins and other b-lactam antimicrobials. The resistance genes encoding these b-lactamases are often located on plasmids and can be horizontally transmitted between bacteria. Infections with ESBL/AmpC-producing bacteria are more difficult to treat.
1,2 ESBL/AmpC-producing microorganisms were first reported from human infections, but subsequent reports on these bacteria in farm animals and companion animals suggested that transmission of these microorganisms or their resistance genes occurs between animals and humans. 3, 4 Livestock is being monitored due to the risk of transmission of resistant bacteria to humans through the food chain, 5 but companion animals and horses have received less attention. Most studies investigating the presence of ESBL/AmpC-producing Enterobacteriaceae in horses refer to clinical isolates. [6] [7] [8] [9] [10] [11] In the UK, the prevalence of faecal carriage of ESBL-producing E. coli was 6.3% among horses in the community. 12 Another study found ESBL-producing E. coli in 32% of the faecal samples at an equine clinic in the Czech Republic, while the prevalence was much lower (9%) at an equine riding centre. 13 Nosocomial spread of ESBL-producing bacteria in equine clinics has been suspected. 9, 13, 14 Circumstantial evidence suggests that transmission of ESBL-producing bacteria between humans and horses occurs. 9, 13 In addition, contact with horses has been identified as a risk factor for carriage of ESBL-producing bacteria in humans. 15 The objective of the present study was to investigate the occurrence and molecular characteristics of ESBL/AmpC-producing E. coli in faecal samples from horses in an equine clinic in order to investigate the potential nosocomial spread of these bacteria.
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Materials and methods

Study population and sampling
Faecal samples from 91 horses were collected during five visits to one equine clinic in the Netherlands between July and October 2015. All horses present at the clinic that had a fresh pile of manure in their box were included. Resident horses were generally only sampled once. Most patients were hospitalized for a short period of time and were therefore only sampled once, with one exception. Samples (30 g) were taken from the top of a pile of freshly passed faeces from each horse and placed in sterile plastic containers. Samples were refrigerated for a maximum of 72 h before further use. The study was performed according to the Dutch law on studies with animals.
Isolation of ESBL/AmpC-producing E. coli A sterile cotton swab stirred through a faecal sample was placed into a sterile tube with 4 mL of Buffered Peptone Water (BPW) (bioTRADING Benelux B.V., Mijdrecht, the Netherlands) supplemented with 1 mg/L cefotaxime (Sigma-Aldrich, Zwijndrecht, The Netherlands). Following selective enrichment for 20+2 h at 37 C, 10 lL was streaked on plates of MacConkey Agar No. 3 (Oxoid B.V., Landsmeer, the Netherlands) supplemented with 1 mg/L cefotaxime and incubated for 20+2 h at 37 C. A maximum of three E. coli colonies were selected based on the diversity of colonies in each plate and transferred to agar plates with 7% sheep blood (Oxoid B.V., Landsmeer, the Netherlands). Isolates were tested for ESBL production by a combination disc diffusion test using cefotaxime and ceftazidime discs, with and without clavulanic acid (BD, Breda, the Netherlands) and according to CLSI guidelines. 16 Additionally, a 30 lg cefoxitin disc was used to detect potential AmpC producers. After incubation for 20+2 h at 37 C, growth inhibition zone diameters were measured and interpreted according to EUCAST. 17 Phylogenetic groups were determined for E. coli isolates according to Doumith et al. 18 and sub-grouped according to Escobar-P aramo et al.
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All phenotypically ESBL-positive isolates were screened by multiplex PCRs to detect the bla CTX-M-1 , bla CTX-M-2 and bla CTX-M-9 group genes, as well as bla OXA , bla SHV and bla TEM gene families. 20 For potential AmpC producers and for isolates that were negative in the PCR screening (n " 27), the Check-MDR CT101 diagnostic system (Check-Points BV, Wageningen, the Netherlands) was used to detect ESBL/AmpC genes according to the manufacturer's instructions.
Molecular characterization of isolates and ESBL/AmpC genes/plasmids
A selection of 129 E. coli isolates were characterized further: one isolate for each different E. coli phylogroup/ESBL gene combination. PCR products were generated using the primers described by Dierikx et al. 6 and treated with ExoSAP-IT (GE Healthcare, Hoevelaken, the Netherlands) and sequenced, and the isolates were genotyped by MLST. 21 Plasmid characterization was performed on a selection of 34 isolates. The selection was made in order to analyse various STs and CTX-M genes to study plasmid diversity as well as potential transmission events. Plasmids were extracted using Qiagen Plasmid Midi Kits (Qiagen, Venlo, the Netherlands) and transformed into competent cells (ElectroMax TM DH10B TM cells; Invitrogen, Landsmeer, the Netherlands) by electroporation, and the resulting transformants were cultured on LB agar (MP Biomedicals, Huissen, the Netherlands) containing 1 mg/L cefotaxime to isolate transformants with an ESBL/AmpC-carrying plasmid, according to Dierikx et al. 22 PCR-based replicon typing (PBRT) was conducted on transformants to identify the replicon type of the plasmid using a commercially available PBRT kit (Diatheva, Fano, Italy; version 12/11/2015), according to Carattoli et al. 23 IncF, IncHI1, IncI1 and IncN plasmids were further characterized by plasmid MLST.
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Results Ninety-one horses were included: 36 patients of the clinic and 55 residents. In total, 98 faecal samples were collected, including duplicate samples from five resident horses (which were sampled twice by accident) and a triplicate sample from a patient with a prolonged stay at the clinic. In addition, a swab from a persistent abdominal wound from one patient was taken. At least one E. coli isolate with a confirmed ESBL/AmpC gene was found in 76 different horses, setting a prevalence of 84% (Table 1 ). An ESBL gene was found in 197 of the total 198 E. coli isolates tested (Table 1) . No E. coli harbouring a plasmidic AmpC gene was recovered.
Twenty-five horses were or had been treated with antimicrobials (Table S1 , available as Supplementary data at JAC Online). Of these, 19 (76%) tested ESBL positive compared with 57 (86%) that had not been treated with antimicrobials. Of the resident horses 48 (87%) tested ESBL positive compared with 28 (78%) of the patients.
Phylogenetic characteristics of isolates
The majority of the isolates belonged to phylogenetic group B1 (73%), followed by group A (19%; A1 18%, A0 1.0%), group D (6.1%, all D1) and group B2 (1.5%, all B2 3 ) ( Table 1 ). The dominant ESBL gene group was bla CTX-M-1 (81%) and it was mainly related to E. coli phylogenetic groups A1 and B1 (16% and 57% of the isolates, respectively). Additionally, phylogenetic group B1 E. coli, carrying a bla CTX-M-2 group gene, constituted another 16% of the isolates.
Molecular characterization of isolates and ESBL genes
A selection of ESBL-producing E. coli (n " 129) from 76 horses were further characterized with respect to their ST and b-lactamase gene subtype (Table 1 ). MLST resulted in 47 different STs including 21 new ones (Table S1 ). The most prevalent STs were ST1250 (n " 21), ST641 (n " 13), ST1079 (n " 12) and ST10 (n " 9). The STs appeared to be distributed randomly among residents and patients ( Figure S1 ).
With regard to the ESBL genes, bla CTX-M-1 was predominant (n " 91), followed by bla CTX-M-2 (n " 26). Moreover, bla CTX-M-14 , bla CTX-M-15 and bla CTX-M-55 were each identified in two isolates. Two isolates from different horses contained a bla CTX-M-1 gene variant (bla CTX-M-1_C462T ). One isolate harboured bla SHV-12 and another isolate bla CTX-M-32 . Furthermore, analysis of the gene sequences showed concurrent presence of more than one bla CTX-M-1 group gene (unassignable by sequencing of PCR products) in two different isolates (ST10 and ST1686).
The phylogenetic relatedness of the identified STs was depicted with a minimum spanning tree (MST) (Figure 1) . Based on the allelic differences, four distinctive clusters of isolates were observed, with STs sharing five to seven alleles. According to Wirth et al., 21 STs with no more than two allelic differences are closely related and assigned in the same clonal complex. The first cluster included the predominant ST1250, together with ST1686, ST4552, ST4164 and ST826 as well as several new STs (n " 46). Another cluster was formed by ST641 and ST86 (n " 15). The third cluster was shaped by ST10 and various STs, including ST744 and ST685 (n " 24). Lastly, the fourth cluster of isolates harboured ST1079 and a new ST (n " 13). Several STs were not included in any cluster, Apostolakos et al.
with the new ST type01 being the most prevalent one (n " 7) (Figure 1 ).
Within-host diversity
Typing of up to three isolates per sample showed that horses often carried ESBL-producing E. coli from two or three different phylogenetic groups concurrently. In total 42 horses carried multiple STs concomitantly. In addition, 23 horses carried two different ESBL genes and in one horse even three different ESBL genes were demonstrated at the same time (Table S1) .
Analysis of samples taken from the same horses but at different timepoints revealed a shift in the genotypes of ESBL-producing E. coli in these animals (Table 2) since different E. coli STs were obtained. In contrast, two sets of identical isolates were identified in both a faecal sample and a swab taken from a persistent abdominal wound of the same horse, namely D1/ST1340 with bla CTX-M-55 as well as A1/ST744 containing bla CTX-M-1 .
Plasmid typing
ESBL plasmids were characterized for 34 isolates. Unfortunately, eight plasmids [carrying bla CTX-M-1 (2), bla CTX-M-14/17 (2), bla CTX-M-2 (4)] did not seem to be transferable, whereas five (all carrying bla CTX-M-1 ) were non-typeable by PBRT (Table 3) . For 21 isolates PBRT analysis revealed the predominant presence of IncHI1 (n " 15) plasmids carrying either bla CTX-M-1 (n " 11) or bla CTX-M-2 (n " 4), among various E. coli STs (Table 3) . Plasmid MLST analysis showed two STs present among these IncHI1 plasmids, i.e. ST9 (n " 12) and ST2 (n " 2, both harbouring bla CTX-M-1 ). In addition, three IncN plasmids all belonging to ST1 were identified in three different E. coli STs, all carrying bla CTX-M-1 . Different IncF plasmids were characterized in two isolates from the same horse at the same time, containing ESBL genes belonging to distinct CTX-M groups, i.e. bla CTX-M-2 and bla CTX-M-55 . Also, an IncI1/ST37 plasmid with bla CTX-M-15 was identified in an E. coli ST1586 (Table 3) . Of the four isolates carrying bla CTX-M-1 derived from the horses sampled at different timepoints (Tables 2 and 3 ) one was transferable but nontypeable by PBRT, one could not be transferred, one was located on IncHI1/ST9 and one on IncHI1/ST2.
Discussion
The most striking result of the present study was the high percentage (84%) of horses carrying ESBL-producing E. coli. Other studies on faecal carriage of ESBL-producing E. coli reported much lower prevalences, ranging from 6.3% for horses in the community to 32% for hospitalized horses, which might partly be explained by the fact that no selective enrichment was used.
12,13 However, Damborg et al. 28 found ESBL-producing E. coli in 10/10 horses following parenteral administration of cefquinome alone or in combination with other antimicrobial agents, although all horses tested negative for ESBL producers before the start of the antimicrobial therapy. Antimicrobial use could increase the numbers Including multiple isolates per horse (see Table S1 ). c Results from a selection of 129 isolates, including multiple isolates per horse (see Tables 2 and 3 and Table S1 ). d The exact allele numbers could not be determined because more than one CTX-M variant was present in this isolate. Table S1 .
High prevalence of ESBL E. coli in horses JAC of resistant E. coli through selective pressure. In the present study 23 horses had received antimicrobials parenterally, one orally and one only locally, but horses that had been treated with antimicrobials were not more often carriers of ESBL-producing E. coli than those that were not treated. Data from the literature support low prevalences of ESBL-producing E. coli in horses in the community and higher ones in hospitalized horses. 12, 13, 29 Indeed, regardless of antimicrobial administration, hospitalization has been demonstrated to be a risk factor for faecal carriage of resistant E. coli. Moreover, the likelihood of colonization by resistant bacteria seems to increase from the time of admission to the first days of hospitalization. 30, 31 Eighty-seven percent of the resident horses, which stayed at the clinic for prolonged periods of time but were generally not treated with antimicrobials and had no or limited contact with the patients, were found to be ESBL positive. ESBL producers might have been already present in the gastrointestinal tract of some of the horses before hospital admission, but the high prevalence suggests that nosocomial spread also played an essential role in the dispersion of ESBL-producing E. coli in the horse clinic, probably through acquisition of such bacteria from other horses, transmission through caretakers or from the clinic's environment. The presence of the same E. coli STs and ESBL genes in Figure 1 . MST analysis of 129 ESBL-producing E. coli isolates based on their MLST allelic profiles. Each circle corresponds to an ST and its size corresponds to the number of isolates. The connecting lines between the circles indicate the relationships between the various STs. Bold solid lines between pairs of STs indicate that they differ in one allele, and two-and three-allele differences are represented by thin solid lines; dashed and dotted lines indicate four or more variable alleles, respectively. New STs with alleles not present in the E. coli MLST database (Table S1 ) have been given artificial allele numbers in order to include them in the MST analysis. The colours of the circles represent the ESBL genes characterized (see colour legend in the figure).
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samples from different horses, some of which were present at the clinic at the same time, also supports the premise of nosocomial spread.
Another important finding was the presence of many different E. coli phylogenetic groups, STs, ESBL genes and plasmid types at this clinic, even within one horse at the same timepoint, but also in the same horse at different timepoints and between different horses. This indicates not only that the high prevalence can be explained by nosocomial spread of one clone, but that horizontal gene transfer between different E. coli strains and/or the presence of multiple reservoirs also played a role. MLST revealed the presence of 47 different E. coli STs, which could be grouped in four major clusters. Fifteen STs were present in residents and patients. This might be due to the fact that these STs are predominant in horses or due to nosocomial spread. The largest cluster was shaped around the predominant ST1250.
The predominant ESBL gene was bla CTX-M-1 , which is in agreement with previous studies on horses.
6,7,13 bla CTX-M-1 has been reported as the predominant ESBL gene in Dutch poultry, 4,22 poultry meat, 3 the general human population 32 and hospital patients. 33 The presence of bla CTX-M-2 in multiple isolates (n " 26) indicates that this gene is emerging in horses, as reported by Smet et al.
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In the present study, four different plasmid PBRT types were identified and further subtyping revealed six types, with IncHI1/ST9 plasmids being most common. IncHI1 plasmids with bla CTX-M-1 have been documented in E. coli isolates from horses, personnel and the environment at an equine clinic in the Czech Republic. 13 IncHI1 plasmids carrying bla CTX-M-2 have been observed in E. coli from diseased horses in Belgium. 10 The same plasmid/gene combination was often found in different horses and in different E. coli STs, suggesting horizontal gene transfer; e.g. IncHI1/ST9 plasmids carrying bla CTX-M-1 were found in different horses on the same day (horses 01 and 02, horses 17 and 20, and horses 50 and 54; Table S1 ), but in different E. coli strains. In horses 19 (patient) and 26 (resident), sampled on the same day, identical E. coli STs carrying the same plasmid/gene combination (ST1861, IncHI1/ST2, bla CTX-M-1 ) were isolated, indicative of clonal transmission and nosocomial spread, although the horses had no direct contact.
In the present study, we characterized multiple isolates per sample and found a large diversity of E. coli genotypes in the same sample (Table S1 ). This was not caused by horizontal transfer during selective enrichment as similar results were found using direct plating (data not shown). This underlines the importance of testing and characterizing different isolates from one sample. Testing only one isolate, which is common practice, leads to an underestimation of the diversity of the genotypes and resistance genes, and can lead to an underestimation of transmission events in the gastrointestinal tract when comparing isolates from different sources.
In conclusion, a very high occurrence of ESBL-producing E. coli was found in horses at a horse clinic and a large diversity of STs, ESBL genes and plasmid types was found, suggesting acquisition through multiple sources and nosocomial spread. These horses could eventually develop difficult-to-treat infections, as demonstrated in horse 58, where identical isolates were cultured from the faeces and a wound. The public health risks of horses carrying ESBL-producing E. coli for persons in close contact, such as veterinarians, caretakers, owners and their family members, is unknown but should be investigated.
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